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Background: It is well-established that what is good for the heart is good for the
brain. Vascular factors such as hypertension, diabetes, and high cholesterol, and
genetic factors such as the apolipoprotein E4 allele increase the risk of developing
both cardiovascular disease and dementia. However, the mechanisms underlying the
heart–brain association remain unclear. Recent evidence suggests that impairments in
vascular phenotypes and cerebrovascular reactivity (CVR) may play an important role
in cognitive decline. The Heart and Brain Study combines state-of-the-art vascular
ultrasound, cerebrovascular magnetic resonance imaging (MRI) and cognitive testing
in participants of the long-running Whitehall II Imaging cohort to examine these
processes together. This paper describes the study protocol, data pre-processing and
overarching objectives.
Methods and Design: The 775 participants of the Whitehall II Imaging cohort, aged
65 years or older in 2019, have received clinical and vascular risk assessments at
5-year-intervals since 1985, as well as a 3T brain MRI scan and neuropsychological
tests between 2012 and 2016 (Whitehall II Wave MRI-1). Approximately 25% of this
cohort are selected for the Heart and Brain Study, which involves a single testing
session at the University of Oxford (Wave MRI-2). Between 2019 and 2023, participants
will undergo ultrasound scans of the ascending aorta and common carotid arteries,
measures of central and peripheral blood pressure, and 3T MRI scans to measure CVR
in response to 5% carbon dioxide in air, vessel-selective cerebral blood flow (CBF), and
cerebrovascular lesions. The structural and diffusion MRI scans and neuropsychological
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battery conducted at Wave MRI-1 will also be repeated. Using this extensive life-course
data, the Heart and Brain Study will examine how 30-year trajectories of vascular risk
throughout midlife (40–70 years) affect vascular phenotypes, cerebrovascular health,
longitudinal brain atrophy and cognitive decline at older ages.
Discussion: The study will generate one of the most comprehensive datasets to
examine the longitudinal determinants of the heart–brain association. It will evaluate
novel physiological processes in order to describe the optimal window for managing
vascular risk in order to delay cognitive decline. Ultimately, the Heart and Brain Study
will inform strategies to identify at-risk individuals for targeted interventions to prevent
or delay dementia.
Keywords: ageing, MRI, cerebrovascular reactivity, cognition, dementia prevention, longitudinal cohort,
ultrasound, heart-brain
INTRODUCTION
The majority of dementia patients have cardiovascular co-
morbidities, and dementia and cardiovascular diseases share
many risk factors (Poblador-Plou et al., 2014). These include
vascular factors such as high blood pressure, high cholesterol,
smoking, diabetes, and physical inactivity, as well as genetic
factors, such as carrying the APOE4 allele (Qiu and Fratiglioni,
2015). Vascular risk is potentially treatable, and managing
it alongside other modifiable lifestyle factors could prevent
an estimated 40% of dementia cases (Livingston et al.,
2020). Prevention on this scale would substantially improve
quality of life for a society which in the next 50 years
is predicted to see a near tripling in the prevalence of
dementia (Patterson, 2018). However, maximizing such dementia
prevention efforts requires an understanding of (1) how and
(2) when in the lifespan vascular risk factors affect brain
and cognitive health, and (3) who is most likely to benefit
from preventative interventions. The Heart and Brain Study
combines detailed vascular phenotyping and state-of-the-art
magnetic resonance imaging (MRI) of the brain in a longitudinal
prospective ageing cohort to investigate these questions with
three overarching objectives.
The first objective is to examine the emerging role of
cerebrovascular regulation in the pathway from vascular risk
to cognitive decline. Impairments in cerebrovascular reactivity
(CVR) have a well-established role in vascular dementia but
growing evidence suggests that CVR can contribute to cognitive
decline and Alzheimer’s disease (Cantin et al., 2011; Yezhuvath
et al., 2012). CVR is the ability of the cerebral blood vessels to
modulate their vasomotor tone to optimize cerebral perfusion in
response to a physiological challenge. This process is essential
for maintaining stable brain oxygenation and is a marker
of the brain’s vascular reserve; higher CVR reflects better
cerebrovascular health (Glodzik et al., 2013). Impairments in
CVR can, over time, result in cerebral hyper- or hypoperfusion,
with the latter being a well-established mechanism in the
dementia pathway, occurring years before the appearance of
clinical symptoms (Iturria-Medina et al., 2016). Studies have
reported reduced CVR in mouse models of Alzheimer’s disease
(Nicolakakis et al., 2008), in Alzheimer’s and vascular dementia
(Coleman and Flood, 1987; Cantin et al., 2011; Yezhuvath et al.,
2012; Gao et al., 2013; Alwatban et al., 2019), and individuals
with established dementia co-morbidities such as stroke,
hypertension, and diabetes (Troisi et al., 1998; Petrica et al., 2007;
Thrippleton et al., 2017). CVR therefore stands to be a powerful
early biomarker of dementia, even preceding established MRI
biomarkers such as hippocampal atrophy. However, there are
still substantial limitations in our understanding of this process.
Most CVR imaging studies have utilized either positron emission
tomography, which is expensive and exposes participants to
ionizing radiation, or transcranial doppler which lacks spatial
resolution and limits an understanding of regional variations in
CVR (Silvestrini et al., 2006; Vicenzini et al., 2007; Gao et al.,
2013; Catchlove et al., 2018). In addition, studies vary in the
choice of vasodilators used to elicit the CVR response; with recent
reviews suggesting that stimuli such as acetazolamide, breath-
holding, and re-breathing may not be as robust or reproducible
as the use of carbon dioxide (CO2)-enriched air (Fierstra et al.,
2013). There have also been calls to assess the tolerability of
and compliance with hypercapnia fMRI challenges in elderly
and at-risk populations (Moreton et al., 2016). Further, while
there is promising evidence supporting a role for CVR in
cognitive impairment, we currently lack an understanding of
the relationship between CVR and (a) circulatory disturbances
in the blood vessels supplying the brain such as the aorta
and carotid arteries, (b) other cerebrovascular anomalies such
as changes in cerebral blood flow (CBF) and vascular lesions,
and (c) longitudinal brain morphology and microstructure.
Examining these processes together would provide insights
into how alterations in system haemodynamics can affect the
brain’s delicate microvasculature. The Heart and Brain Study
uses the latest advances in non-invasive and spatially sensitive
blood oxygen level dependent (BOLD) fMRI to measure CVR
in response to a 5% CO2 stimulus in order to overcome
these methodological limitations and address the gaps in our
current understanding.
The second objective of this study is to further understand
the temporal dynamics of dementia risk factors. Risk factors
have been shown to have different effects across the life course.
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For instance, while mid-life cholesterol, blood pressure and
obesity are associated with higher dementia incidence, later-
life measures of these risk factors are associated with a lower
incidence of dementia (Martín-Ponce et al., 2010). This is
interesting as it suggests that risk factors may also have age-
specific effects on the underlying cerebrovascular anomalies,
possibly depending on whether the factors have been assessed
before or during the preclinical stage of dementia. Indeed, we
have previously shown age effects of vascular risk factors on
grey matter (GM) volume, white matter (WM) microstructure
(Zsoldos et al., 2020), cerebral perfusion (Suri et al., 2019) and
clinical dementia (Singh-Manoux et al., 2017). However, there
is an evident lack of longitudinal neuroimaging studies which
assess the age-specific effects of dementia risk on CVR and other
measures of cerebrovascular ageing. The Heart and Brain Study
will investigate these age-specific effects by recruiting participants
from the longitudinal Whitehall II Imaging Study, who have
already received detailed clinical follow-ups every 5 years starting
from mean age 47.8 years (at Wave 3), as well as a multi-modal
brain MRI scan and neuropsychological tests at mean age 70 years
(2012–2016) (Marmot and Brunner, 2005; Filippini et al., 2014).
By capitalizing on this uniquely comprehensive dataset, the study
will examine the association of 30-year antecedent trajectories
of vascular risk with cerebrovascular regulation and cognitive
decline in older age.
Third, on the question of personalised interventions, it has
been shown that lifestyle modifications may be more beneficial
for APOE4-carriers than non-carriers, however, the reasons
for this remain unclear (Brown et al., 2012; Gardener et al.,
2015). Interestingly, both younger (Suri et al., 2014a) and older
(Hajjar et al., 2015; Wolters et al., 2016). APOE4 carriers have
been shown to have lower CVR than non-carriers. This is
important because impairments in CVR are likely reversible
through exercise interventions (Ivey et al., 2011; Murrell et al.,
2013), statins (Forteza et al., 2012), and acetylcholinesterase
inhibitors such as galantamine and donepezil (Rosengarten et al.,
2006; Bar et al., 2007), the latter being established treatments
for Alzheimer’s disease. This evidence (albeit preliminary)
positions CVR as a promising early marker for identifying at-risk
individuals eligible for targeted interventions, and as a relevant
surrogate endpoint in clinical trials. This study will therefore
examine whether associations between CVR, vascular risk and
cognitive impairment are moderated by the presence of the
APOE4 risk allele.
In this paper, we describe the design, organisation, and
participant inclusion criteria for the Heart and Brain Study.
We present the protocols for acquisition and pre-processing
of vascular measurements, MRI scans, and cognitive and
mental health assessments. We discuss preliminary findings
on the feasibility of hypercapnia fMRI and describe the key
hypotheses for the study.
METHODS AND ANALYSIS
Study Design
Participants of the Heart and Brain Study are selected from
the Whitehall II Imaging Sub-study cohort (Filippini et al.,
2014). This cohort comprises 775 retired British civil servants
who received multi-modal brain structural and functional MRI
scans as well as a detailed battery of cognitive tests and mental
health assessments between April 2012 and December 2016
at the Centre for Functional Magnetic Resonance Imaging of
the Brain (FMRIB), now part of the Wellcome Centre for
Integrative Neuroimaging (WIN), University of Oxford. Cohort
participants have also undergone repeated longitudinal clinical
and cognitive testing since 1985, across 13 Waves of the parent
Whitehall II Study at University College London (Marmot and
Brunner, 2005). A description of the longitudinal study design
and measures collected at the Waves which included clinical
follow-ups are provided in Figure 1. The Heart and Brain Study
will recruit 200 participants from the Wave MRI-1 cohort for a
follow-up visit at the Oxford Centre for Human Brain Activity
(OHBA) within the WIN. For consistency, the Whitehall II
Imaging Sub-study and the Heart and Brain Study waves will
be referred to as “Wave MRI-1 (2012–2016)” and “Wave MRI-2
(2019–2023),” respectively.
The testing protocol for the Heart and Brain Study consists
of a single 3-h session comprising a 45-min MRI scan, 1 h of
physiological and vascular measurements, 1 h of cognitive tests,
and a self-administered health questionnaire that is completed at
home in the week prior to the testing appointment (Table 1).
Due to an MRI scanner upgrade two-thirds of the way through
Wave MRI-1, two scanners were used for the baseline scans: a 3T
Siemens Magnetom Verio scanner with a 32-channel head coil
(n = 552, April 2012–December 2014) and a 3T Siemens Prisma
Scanner with a 64-channel head-neck coil, both at the FMRIB
Centre, Oxford (n = 223, July 2015–December 2016) (Filippini
et al., 2014). Wave MRI-2 is conducted on a 3T Prisma scanner at
the OHBA Centre, Oxford. All core imaging sequences have been
matched as closely as possible between scanners and are described
in Table 2.
The study design was informed by Patient and Public
Involvement (PPI), with a focus group of 5 participants including
dementia support workers, patients, and carers. The study was
piloted between July to September 2018, with 6 participants
aged >65 years old, recruited through the Oxford Dementia and
Ageing Research (OxDARE)1 database and mailing lists (CUREC
Ethics Reference for pilot study: R58145). The PPI focus group
and pilot were used to determine testing duration, feasibility and
the protocols for the hypercapnic stimulus challenge.
Selection of Participants
Postal invitations were sent to all 775 participants between
July and October 2019. All participants undergo a telephone
screening before their visit, during which exclusion criteria are
evaluated, including contraindications to MRI (e.g., pacemaker,
claustrophobia), respiratory contraindications which may affect
their ability to perform a hypercapnic challenge (e.g., severe
asthma, chronic obstructive pulmonary disease), and a clinical
diagnosis of dementia.
Of the selection pool of 775, participants are excluded for
Wave MRI-2 if they died or withdrew from the Whitehall II
Study at Wave 13 or if they have gross incidental findings
1https://www.oxdare.ox.ac.uk/home
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FIGURE 1 | Study and cohort design. Clinical and vascular risk information was collected at the seven out of 13 waves of the Whitehall II Study, marked in black.
APOE genotyping was performed at Wave 7. Brain MRI and cognitive assessments were collected at Wave MRI-1 (Whitehall II Imaging Sub-study), marked in green.
A sub-set of the MRI and cognitive protocol are repeated at Wave MRI-2 (Heart and Brain Study), with novel cerebrovascular MRI and vascular ultrasound scans,
marked in orange. *Indicates waves that are in progress at the time of publication.
such as large strokes, tumours or cysts on their MRI-1 scan.
Participants are prioritised for recruitment to Wave MRI-2 if
they have complete information for key variables of interest in
this study (APOE genotype, midlife vascular risk information
at Waves 3 or 5, and complete T1-weighted, diffusion tensor
imaging (DTI) and FLAIR scans at Wave MRI-1). Participants
are also prioritised for recruitment if they were scanned on the
Verio scanner at Wave MRI-1, as the Verio pool (a) received
their baseline scans earlier on, allowing greater time to follow up,
and (b) is larger, allowing us to reach the study’s initial target of
N = 200.
Due to the COVID-19 pandemic, the Heart and Brain Study
was temporarily paused in March 2020 after recruiting 22
participants. Analysis protocols developed with this data are
presented in the following sections. The study will resume when
risk assessments in line with national pandemic guidelines in the
United Kingdom indicate it is safe to do so.
Midlife Vascular and Genetic Risk for
Dementia
Midlife vascular risk is assessed using composite risk scores
calculated at Waves 3–11. Scores such as the Framingham
Cardiovascular Disease Risk Score (FRS, comprising age, sex,
body mass index (BMI), systolic blood pressure, total and
HDL cholesterol, diabetes, smoking, antihypertensive treatment)
(D’Agostino et al., 2008) and the CAIDE Dementia Risk Score
(comprising age, sex, education, total cholesterol, BMI, systolic
blood pressure, and physical activity) are used (Kivipelto et al.,
2006). Both risk scores combine known risk factors for dementia
and have been shown to predict cognitive decline and dementia
within the Whitehall II cohort (Kaffashian et al., 2011) and other
cohorts (Exalto et al., 2014). At Wave 3, approximately 29% and
34% of the MRI-1 cohort are classed as having moderate-to-
high cardiovascular risk (FRS≥ 10) and modifiable dementia risk
(CAIDE ≥ 6), respectively.
Genetic risk is assessed as presence of the APOE4 allele, the
best-established genetic risk variant for late-onset Alzheimer’s
disease. APOE genotyping was performed at Wave 7 of the
Whitehall II Study and the procedure has been described in
detail elsewhere (Filippini et al., 2014). Of in the Wave MRI-1
cohort, 663 out of 775 participants have available APOE genotype
information, 24.8% (157/633) are APOE4-carriers (defined as
ε3ε4 or ε4ε4), 73.3 % are non-carriers (defined as ε3ε3, ε2ε3, and
ε2ε2), and 1.8% are ε2ε4 carriers.
3T Brain MRI
Magnetic resonance imaging scans for the Heart and Brain
Study are acquired using a 3T Siemens Prisma scanner at the
OHBA. Scans are processed using FMRIB Software Library (FSL)
(Jenkinson et al., 2012) and FreeSurfer (Fischl et al., 2002;
Reuter et al., 2012), and visually inspected in FSLeyes (McCarthy,
2020), with reference to pipelines adapted from the Whitehall II
Imaging Sub-study and the UK Biobank Study (Alfaro-Almagro
et al., 2018)2. To reduce spatial distortions, a gradient distortion
correction (GDC) is applied to scans3 using a proprietary Siemens
data file that describes gradient non-linearities. To protect
participant anonymity, all high-resolution scans are “defaced” to
remove the eyes, nose, mouth and ears using the “fsl_deface” tool.
2https://git.fmrib.ox.ac.uk/falmagro/UK_biobank_pipeline_v_1
3https://github.com/Washington-University/HCPpipelines/wiki/FAQ
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TABLE 1 | Assessments for the Whitehall II Imaging Sub-study (Wave MRI-1) and
Heart and Brain Study (Wave MRI-2).
Wave MRI-1 Wave MRI-2






Montreal Cognitive Assessment X X
Trail Making Test, A and B X X
Rey Complex Figure Test X X
Categorical Fluency Test (animals) X X
Hopkins Verbal Learning Test-R X X
Boston Naming Test-60 X X
Digit Span X X
Digit Coding Tests X X
Test of Premorbid Functioning X X
Dots and Letters X
Executive Clock Drawing Task (CLOX) X





Central blood pressure X
Body mass index X X









Resting-state MB6 BOLD X






General Health Questionnaire X X
Mood Disorder Questionnaire X X
Centre for Epidemiological Studies
Depression Scale
X X
State and Trait Anxiety Inventory X X
Physical Activity Questionnaire for Older
Adults
X X
Locus for Causality Exercise
Questionnaire
X X
Pittsburgh Sleep Quality Index X X
Jenkins Sleep Questionnaire X X
Life-Orientation Revised X X




Penn State Worry Questionnaire X X
Handedness X X
(Continued)
TABLE 1 | Continued
Wave MRI-1 Wave MRI-2







Alcohol and smoking X X
5-Dimensional Curiosity Scale X
Demographics (age, sex, and
education)
X X
PCASL: pseudocontinuous arterial spin labelling; BOLD: blood oxygen level
dependent, MB6: multiband acceleration factor 6.
Image acquisition parameters at Waves MRI-1 and MRI-2 are
presented in Table 2.
Structural Imaging
T1-weighted imaging
T1 scans provide information about tissue morphology and
volumes and are an essential step in the processing of almost
all other MRI modalities. A 1 mm isotropic 3D MPRAGE scan
is acquired using the “pre-scan normalise” option to perform
partial bias field correction during acquisition (van der Kouwe
et al., 2008). At both the MRI-1 and MRI-2 waves, GDC-
corrected and defaced images are re-oriented to MNI152 space,
cropped to reduce the amount of non-brain tissue, bias-field
corrected, registered to the 1 mm standard MNI152 space using
non-linear registration, and brain-extracted using the inverse of
the MNI152 alignment warp to generate a brain-extracted T1.
All of the above is performed using the automated FSL-ANAT
tool. The pre-processed images are then segmented to produce
partial volumes for total GM, WM, cerebrospinal fluid (CSF), and
sub-cortical regions. Subsequently, volumes can be extracted in
mm3 and normalised as percentages of total brain (GM+WM)
volume and total intracranial volume (GM + WM + CSF).
As the T1 acquisitions at Wave MRI-2 have brighter carotid
arteries than those at MRI-1, we perform an additional “intensity
clipping” step for harmonization. Briefly, we create a custom
brain mask that excludes these arteries before estimating regional
and local volumes.
To investigate longitudinal atrophy between Waves
MRI-1 and MRI-2, established pipelines which incorporate
additional temporal information will be used. These include
the FreeSurfer Longitudinal Pipeline (Reuter et al., 2012),
which estimates reliable changes in volume and thickness for
cortical and subcortical regions; the FSL-SIENA tool which
estimates percentage brain volume change between two time
points (Smith et al., 2002), and the modified voxel-based
morphometry pipeline to assess voxel-wise microstructural
changes (Chételat et al., 2005).
Diffusion tensor imaging
Diffusion tensor imaging is sensitive to the anisotropic diffusion
of water within the axon, i.e., the diffusion is unrestricted along
the axon, but hindered perpendicularly due to the myelin sheath.
The directionality and magnitude of water diffusion is quantified
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TABLE 2 | Acquisition parameters of the core MRI sequences at Waves MRI-1 and MRI-2.
MRI Wave MRI-1 3T Verio Wave MRI-1 3T Prisma Wave MRI-2 3T Prisma
Study name Whitehall II Imaging Whitehall II Imaging Heart and Brain Study
Duration April 2012–December 2014 July 2015–December 2016 October 2019–2023
N 550 225 200
Head coil 32-channel 64-channel 64-channel
Structural T1 MEMPR MPRAGE MPRAGE
Voxel, mm3 1 × 1 × 1 1 × 1 × 1 1 × 1 × 1
TR, ms 2,530 1,900 1,900
TE, ms 1.79/3.65/5.51/7.37 3.97 3.97
TI, ms 1,380 904 904
Flip angle,◦ 7 8 8
Field of view, mm 256 192 192
Acquisition time 6 min 12 s 5 min 31 s 5 min 31 s
Diffusion MRI
Voxel, mm3 2 × 2 × 2 2 × 2 × 2 2 × 2 × 2
TR/TE, ms 8,900/91.2 8,900/91 8,900/91
b-value, s/mm2 1,500 1,500 1,500
N volumes (A >> P) 60 + 5b = 0 s 60 + 5b = 0 s 60 + 5b = 0 s
N volumes (P >> A) 1b = 0 1b = 0 1b = 0
Field of view, mm 192 192 192
Acquisition time 9 min 56 s 10 min 5 s 10 min 5 s
FLAIR
Voxel, mm3 0.4 × 0.4 × 3.0 0.4 × 0.4 × 3.0 0.4 × 0.4 × 3.0
TR/TE, ms 9,000/73 9,000/73 9,000/ 73
TI, ms 2,500 2,500 2,500
Flip angle, ◦ 150 150 150
Field of view, mm 220 220 220
Acquisition time 4 min 14 s 4 min 14 s 4 min 14 s
Fieldmaps
Voxel, mm3 3 × 3 × 3 3 × 3 × 3 3 × 3 × 3
TR, ms 400 378 590
TE, ms 5.19/7.65 4.92/7.38 4.92/7.38
Flip angle, ◦ 60 45 46
Field of view, mm 258 192 216
Acquisition time 1 min 11 s 49 s 1 min 26 s
Respiratory-calibrated BOLD functional MRI
Voxel, mm3 – – 2.4 × 2.4 × 2.4
TR/TE, ms – – 800/30
Flip angle, ◦ – – 52
Field of view, mm – – 216
Multi-band acceleration factor – – 6
N volumes – – 450
Acquisition time – – 6 min 8 s
Vessel-encoded pCASL*
Voxel, mm3 – – 3.4 × 3.4 × 4.5
TR/TE, ms – – 4,400 (variable)/14
Labelling duration, ms 1,400
Phase partial Fourier – – 6/8
Post-labelling delays, ms – – 250/500/750/1,000/1,250/1,500/1,750
Slices – – 24
Time per slice, ms – – 45.2
Echo spacing, ms – – 0.56
Field of view, mm 220
(Continued)
Frontiers in Physiology | www.frontiersin.org 6 March 2021 | Volume 12 | Article 643725
fphys-12-643725 March 31, 2021 Time: 17:28 # 7
Suri et al. The Heart and Brain Study
TABLE 2 | Continued
MRI Wave MRI-1 3T Verio Wave MRI-1 3T Prisma Wave MRI-2 3T Prisma
N volumes (A >> P) – – 112 + 1 M0
N volumes (P >> A) – – 1 M0
Acquisition time – – 6 min 44 s
TRUST
Voxel, mm3 – – 3.4 × 3.4 × 5
TR/TE, ms – – 3,000/7
Acceleration factor – – GRAPPA = 3
Phase partial Fourier – – 6/8
Slab thickness/gap, mm – – 100/25
Echo spacing, ms – – 0.49
TI, ms – – 1,020
Flip angle, ◦ – – 90
Field of view, mm – – 220
Acquisition time – – 1 min 27 sec
MRI: magnetic resonance imaging, TR: repetition time, TE: echo time, TI: inversion time, A: anterior, P: posterior, FLAIR: Fluid-attenuated inversion recovery, BOLD: blood
oxygen level dependent, pCASL: pseudocontinuous arterial spin labelling, TRUST: T2-relaxation-under-spin-tagging MRI.
*A subset of 145 out of the 552 participants at Wave MRI-1 on the Verio scanner also received pCASL scans (not vessel-encoded), the protocol for which is described in
detail previously (Suri et al., 2019).
by DTI-derived metrics such as fractional anisotropy (FA), radial
diffusivity (RD), axial diffusivity (AD), and mean diffusivity
(MD). Decreases in FA alongside increases in diffusivity are
well-established measures of WM impairments in dementia
(Suri et al., 2014b).
Diffusion tensor imaging scans are processed as described
for Wave MRI-1 and the UK Biobank Study. Briefly, scans
are analysed using the FMRIB diffusion toolbox (Smith
et al., 2006), which performs susceptibility-induced distortion
correction using FSL-TOPUP, brain extraction on the distortion-
corrected B0 image using FSL-BET, and motion and eddy
current correction using FSL-EDDY (Behrens et al., 2003).
A single reverse (posterior-to-anterior) phase-encoding non-
diffusion weighted (b-value = 0 s/mm2) volume is acquired, to
generate appropriate fieldmaps for the “topup” tool. The resulting
aligned and distortion corrected diffusion images are fed into
“dtifit”, which fits a diffusion tensor model at each voxel and
produces FA and diffusivity maps. These maps are then entered
into the TBSS pipeline to perform microstructural analysis
across subjects. FA maps are aligned to standard FMRIB58_FA
space using FNIRT and thinned to create a mean FA skeleton
representing the centres of all WM tracts common to the group.
This is then repeated for MD, RD and AD. Measures of global
FA, MD, RD and AD can then be extracted from the mean
skeleton, and the respective subject-specific spatial maps can




In this study, CO2-CVR is measured as the compensatory change
in the BOLD signal in response to a 5% CO2 challenge. The
respiratory paradigm consists of 60 s of air followed by two 75 s
blocks of hypercapnia interleaved with two 75 s blocks of air.
Multi-band BOLD fMRI scans are acquired every 800 ms during
the respiratory challenge (see Table 2 for acquisition parameters).
Participants are asked to lie still with their eyes open, and to
breathe normally during the scan as both posture (Favre et al.,
2020) and eye opening (Peng et al., 2013) have been shown to
affect the BOLD response.
Inspired gases are delivered to a face mask at a rate of
15 L/min via a unidirectional breathing circuit designed in-
house at the University of Oxford using parts from Intersurgical
Ltd., Wokingham, United Kingdom (Figure 2). A gas analyser
(ML206, ADInstruments, New Zealand) and data acquisition
system (PowerLab 4/35, ADInstruments, New Zealand) are
connected to the face mask via a sampling line and used to
obtain continuous recordings of inspired and expired oxygen
and CO2 concentration throughout the scan. This produces
a full respiratory trace from which end-tidal values are
subsequently obtained.
The gas delivery system consists of a cylinder of synthetic
medical air (191-J, BOC Limited, United Kingdom) and one
of 5% CO2 in medical air (299034-L-PC, BOC Limited,
United Kingdom), each fitted with a pressure regulator
(Gasarc Tech-Master, ESAB, United Kingdom) and connected
to a variable area flow meter (99-0377, The Gas Safety Co,
United Kingdom) via a solenoid valve (Type 6013, Bürkert,
Germany). The valves are operated by an automated valve
controller designed in-house, programmed with the respiratory
paradigm, and triggered directly by the MRI scanner. From the
flow meters, the gases are piped into the breathing circuit shown
in Figure 2.
The breathing circuit consists of a disposable anaesthetic face
mask placed over the participant’s mouth and nose and fastened
with a harness. The mask is connected to a disposable elbow
piece with a sampling port linked to the data acquisition system,
allowing gas concentrations to be measured continuously. The
elbow piece also connects to a disposable T-piece, with a one-
way outlet valve on one leg (providing an unimpeded path for
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FIGURE 2 | Breathing circuit for the CO2-CVR respiratory paradigm, and the corresponding product identification numbers from Intersurgical Ltd., Wokingham,
United Kingdom.
expired air) and a one-way inlet valve on the other leg (supplying
the inspired gas). A medical grade breathing filter is placed
at the junction of the disposable circuitry and the fixtures, to
prevent cross-contamination of the fixtures. The circuit is open
to room air via an additional length of tubing that serves as a
gas reservoir. This guarantees that participants are safely able to
continue breathing if the gas flow is unexpectedly interrupted
or insufficient.
In order to familiarize participants with the hypercapnia
challenge and check for leaks in the breathing circuit, we briefly
deliver the gases to participants for a test period before they enter
the MRI scanner. Leaks at the mask-face interface identified via
the capnometry trace are plugged with additional rubber fittings
if needed. During the scan, heart rate, and respiratory effort
are monitored non-invasively using a pulse plethysmograph and
chest belt. The participant’s respiratory trace is observed for
indications of stress, and they are provided with a buzzer to
request immediate removal from the scanner at any point.
Figure 3 describes the data analysis for a single participant.
Each participant’s respiratory trace is processed using an in-house
MATLAB script (Bulte et al., 2012; Suri et al., 2014a) which
extracts the end-tidal CO2 (EtCO2) values, then interpolates,
trims, shifts and resamples the data to align with the BOLD
time course and TR. This produces one EtCO2 value per
fMRI volume. These data are then normalised to use as a
regressor. The raw fMRI data is processed with FSL-FEAT, which
performs motion correction, brain extraction, spatial smoothing
(here, using a kernel of 4 mm), high-pass temporal filtering
(here, using a cut-off 210 Hz, representing one 60s baseline
block + one 75s hypercapnia block + one 75s normocapnia
block), and distortion correction using fieldmaps processed
with the “fsl_prepare_fieldmap” tool. The normalised EtCO2
values are entered as explanatory variables in FEAT, which uses
general linear modelling to fit the experimental design to the
associated BOLD time-course. This ultimately highlights the
brain regions which show a response to the hypercapnic stimulus.
For each subject, mean CVR is then extracted from regions
of interest using Featquery, and expressed as the percentage
change in BOLD signal per mmHg change in EtCO2 (%BOLD
/1EtCO2 mmHg), where the total change in EtCO2 is the
difference between the mean baseline value and the mean of the
maximum change in the two hypercapnic periods. The processed
fMRI images can also be registered to standard MNI152 space
and submitted for cross-subject voxel-wise statistics using higher-
level FEAT analyses.
Feasibility and tolerability of CO2-CVR scan
Immediately after their MRI scan, participants complete a
questionnaire to rate their experience of breathlessness, anxiety,
claustrophobia and discomfort during the respiratory paradigm
on a scale of 0–10 (0–3 low discomfort, 4–7: moderate
discomfort, 8–10: severe discomfort). The full questionnaire is
presented in the Supplementary Materials and was developed
together with the Imaging Cerebral Physiology Network4. Of the
22 participants scanned thus far, one participant did not complete
the questionnaire due to time constraints, and responses from the
remaining 21 participants are presented in Figure 4. Overall, 24%
(5/21) of participants noticed when they were breathing different
gases, but only 5% (1/21) noticed a change in smell or taste. In an
open-ended question about the least comfortable part of the CVR
scan, 43% (9/21) participants mentioned general scanner-related
sources of discomfort such as scanner noise and difficulty lying
still or staying awake, 43% (9/21) participants mentioned feeling
restricted or breathless due to the mask and gases, and 14% (3/21)
stated that they experienced no discomfort. Importantly, when
4http://www.icp-network.org/
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FIGURE 3 | Analysis of CVR scans. (A) The 6-min end-tidal CO2 (EtCO2) capnometry trace for a Heart and Brain Study participant. Each blue peak represents one
breath and the red line follows the EtCO2 at expiration, resampled at the TR. Participants inhaled either normocapnic air (0.04% CO2) or air mixed with 5% CO2
through a face mask. For the first 60 s participants inhaled air, followed by two alternating 75 s blocks of 5% CO2 in air, and air. MRI data was collected from 0s.
(B) Normalised and averaged EtCO2 at each TR, used as an explanatory variable in fMRI analysis. (C) Thresholded activation images, showing a BOLD signal
change during the hypercapnia blocks relative to air. Red to yellow colours represent 3.1 < z-statistic < 26.8.
FIGURE 4 | Tolerability of the CO2-CVR scan. Plots show responses from 21 participants of the Heart and Brain Study stating (A) the level of discomfort (rated from
0 to 10) related to the different symptoms during a 5% CO2 challenge and (B) the willingness to participate in a similar respiratory-calibrated MRI study again.
Responses suggest that a 6-minute respiratory paradigm with a 5% CO2 challenge is generally well-tolerated and feasible in older adults.
asked whether they would be willing to participate in a similar
study again, 90% (19/21) said “Yes”, 1 participant said “Maybe”
and only 1 answered “No”, due to mask-related claustrophobia.
Taken together these responses suggest that a 6-min respiratory
paradigm with a 5% CO2 challenge is generally well-tolerated and
feasible in adults aged > 65 years old, who have a range of risk
factors for dementia.
Vessel-encoded cerebral perfusion (pseudocontinuous
arterial spin labelling)
Cerebral blood flow is typically measured non-invasively
using pseudocontinuous arterial spin labelling (pCASL), which
quantifies total perfusion as the rate of delivery of arterial blood
to brain tissue (millilitres of blood per 100 g of tissue per minute)
(Alsop et al., 2015). Recent advances in pCASL imaging offer
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additional vessel-specificity, so that in addition to obtaining
measures of total CBF, we can also image and quantify perfusion
from each of the four major arteries supplying the brain, viz.
the right and left internal carotid arteries and vertebral arteries.
Vessel-encoded pCASL has the added advantage of assessing
(a) variations in vascular territories in individuals with differing
dementia risk (b) compensatory collateral flow as a result of
underlying vascular disease, which is not otherwise possible with
pCASL scans of total cerebral perfusion (Okell et al., 2013; Jezzard
et al., 2017). Vessel-encoded scans also provide more accurate
perfusion estimates in cases where there is mixed blood supply,
and the arterial arrival time from each artery differs.
We acquire a multi post-labelling delay (PLD) vessel-encoded
pCASL scan with a labelling duration of 1.4 s, and 7 PLDs (0.25,
0.50, 0.75, 1.0, 1.25, 1.5, and 1.75 s) with two averages of 8 vessel-
encoding cycles at each PLD (i.e., 7 PLDs× 8 encoding cycles× 2
averages for each PLD/encoding pair = 112 volumes). A 3D
multi-slab time-of-flight sequence is acquired immediately prior
to the pCASL scan to enable localisation of the labelling plane and
vessels. The four arteries are labelled in different combinations
during acquisition, as described previously (Okell et al., 2013),
and the contribution of each artery to the resulting signal is
decoded in post-processing using the VEASL tool within the
BASIL (Bayesian Inference for Arterial Spin Labelling) toolkit
(Chappell et al., 2009, 2010, 2012). BASIL uses a variational Bayes
approach to perform a nonlinear fit of the general kinetic model
to the pCASL data for all voxels in the brain. One M0 calibration
scan is acquired to calibrate the pCASL perfusion-weighted signal
by estimating the equilibrium magnetization of blood, and a
single reverse phase-encoded (P >> A) calibration scan with
the same parameters is acquired for distortion correction using
the FSL “topup” tool (Andersson et al., 2003). The analysis of
vessel-encoded pCASL data is similar to that of pCASL scans
(Suri et al., 2019) with an additional step to decode the vessel
contributions after pre-processing, and fitting the kinetic model
to each vessel component separately. The vessel decoding process
has been described in detail previously (Chappell et al., 2010;
Okell et al., 2013).
Figure 5 displays the vessel-encoded pCASL output from
a single participant at Wave MRI-2. A file containing the X
and Y coordinates of the initial locations of the four encoded
vessels is generated from the DICOM perfusion data. Raw scans
are acquired using the “Pre-scan normalise” option and pre-
processed using the “oxasl” tool, with which the images are
averaged, decoded, and used to generate artery-specific perfusion
maps. Recommended fixed values for T1 of tissue (1.3s) and
blood (1.65s) are used (Alsop et al., 2015). The arterial transit
time for each feeding artery is estimated voxel-wise from the
data assuming a prior mean of 1.3 s, as per previous studies
(Okell et al., 2013; Harston et al., 2017). A weighted whole-brain
arterial transit time map is calculated can then be calculated
as described previously and used for cross-subject voxel-wise
statistics (Okell et al., 2013). Slice timing correction (an increase
in PLD of 0.0452s per slice) is applied (Groves et al., 2009).
The T1 scans are used to automatically define the CSF in the
ventricles and the calibration image is used to calculate the
equilibrium magnetization of ventricle CSF in the ventricles. This
is converted to the equivalent value in arterial blood (accounting
for differences in proton density) and used to give perfusion
values in absolute units of ml/100 g/min for each vessel. The
output of the individual vessels is summed to give total cerebral
perfusion in each voxel in native ASL space.
To run cross-subject voxel-wise statistics, ASL scans are
registered to standard MNI152 space. Partial volume effects
can arise from the typically low spatial resolution of pCASL
data and are a potential confounding factor given the tissue-
specific kinetics (WM tends to have lower CBF and longer
arrival times than GM). This can be particularly complicated in
populations with age-related atrophy, thus an automatic partial
volume correction will be applied (Chappell et al., 2011). This
uses high-resolution partial volume estimates from the structural
image to produce separate GM and WM perfusion maps in native
and standard space. Results with and without partial volume
correction will be analysed.
White matter hyperintensities
FLAIR scans provide information on white matter
hyperintensities (WMHs), a key pathology of vascular and
Alzheimer’s dementia (Wardlaw et al., 2015). Here, WMHs
are quantified using the FSL-BIANCA tool, a fully automated,
supervised tool for WMH segmentation, based on the k-nearest
neighbour algorithm (Griffanti et al., 2016). BIANCA has been
optimised on two clinical datasets, applied in healthy older adults
(Griffanti et al., 2018), and trained using an openly available
training dataset (“Mixed_WH-UKB_FLAIR_T1”, available at5,
Bordin et al., 2020). The training dataset was generated using
FLAIR, T1 and manually segmented WMH images from a sub-
sample of 24 participants each from the Whitehall II Imaging
Sub-study Siemens Verio 3T scanner, the Prisma 3T scanner,
and 12 participants from the UK Biobank Study (Siemens Skyra
3T). Training BIANCA with this dataset reduces the variability
in BIANCA performance and generates more consistent WMH
measures across images acquired in different cohorts and
scanners (Bordin et al., 2020).
To quantify the WMH load, we first create a WM mask in
T1 space, which excludes cortical and subcortical GM (details in
Griffanti et al. (2016)). This mask, together with bias-corrected
and brain-extracted T1 images and T1 brain masks, is then
linearly registered to FLAIR space using FLIRT. The GDC-
corrected and defaced FLAIR scans are brain-extracted (by
applying the registered T1 brain mask) and bias-corrected. They
are then masked using the WM mask generated in the first step
in order to reduce the detection of false positive hyperintensities
from cortical and subcortical GM. For each subject, BIANCA
is run using the masked FLAIR image, the brain-extracted T1
image and a FLAIR-to-MNI transformation matrix. This pipeline
classifies voxels by their intensity and spatial features, producing
a map with the probability of each voxel being a WMH. The
probability maps are subsequently thresholded at 0.8 or 0.9 based
on a visual assessment of WMH load (higher WMH load requires
lower thresholds) and then binarized. WMH volumes are then
extracted in mm3 and expressed as % of total brain volume
(WM+ GM) and total intracranial volume (WM+ GM+ CSF).
5https://issues.dpuk.org/eugeneduff/wmh_harmonisation/-/tree/master/
BIANCA_training_datasets
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FIGURE 5 | Vessel-encoded pCASL data from a Heart and Brain Study participant. The top panel displays total cerebral perfusion in ml/100 g tissue/min across six
horizontal slices in native ASL space. Warmer colours representing regions of higher perfusion. The middle panel displays perfusion from each of the four encoded
vessels for a single slice (RVA, LVA: right and left vertebral arteries, RICA, LICA: right and left internal carotid arteries). The bottom panel displays combined vascular
territory maps where signals from each of the four feeding arteries are summed (green: LICA, red: RICA, blue: RVA, and magenta: LVA).
Evaluation of BIANCA performance across scanners
Although the same FLAIR sequence was used at both the
MRI waves and a harmonised training dataset was used, we
performed further evaluations of BIANCA to ensure that it
was performing equally well on images from the scanners at
MRI-1 (3T Verio) and MRI-2 (3T Prisma) (Griffanti et al.,
2016). We created manually segmented WMH masks for 12
participants of the Heart and Brain Study, who had a range of
WMH loads at Waves MRI-1 and MRI-2. We then measured the
volumetric agreement between the total WMH volume obtained
from BIANCA and manual segmentations using the intra class
correlation coefficient (ICC; two-way mixed model with absolute
agreement definition). BIANCA performance was also evaluated
by testing the interaction between manually segmented WMH
volumes (independent variable) and MRI wave on the Dice
Similarity Index, DSI (dependent variable; a summary measure
of overlap between manual and BIANCA segmentations).
Similar regression slopes (i.e., no interaction between MRI wave
and WMH volumes) and regression intercepts (i.e., no main
effect of MRI wave) would indicate successful between-scanner
harmonisation.
DSI =
2× (voxels in the intersection of manually
segmented and BIANCA segmented masks)
voxels in the manual mask+
voxels in the BIANCA mask
(1)
Overall, there was an excellent agreement between manual and
BIANCA segmentations at Wave MRI-1 (ICC [95% CI] = 0.97
[0.87, 0.99]) and Wave MRI-2 (ICC [95% CI] = 0.98 [0.66, 0.99]).
The volume in mm3 of WMHs was significantly higher at MRI-
2 than in MRI-1, for both the manual segmentations (paired
t(11) = 4.7, difference of the means [95% CI] = 2,024.1 [1,065.1–
2,983.0], p < 0.001) and automatic BIANCA segmentations
(t(11) = 5.1, difference of the means [95% CI] = 2,447.9 [1,396.6–
3,499.2], p < 0.001). Despite the increase in the WMH load,
BIANCA performed similarly across both the timepoints and
scanners, as evidenced by (a) the overlapping linear regression
lines at the MRI-1 and MRI-2 waves (Figure 6), (b) no main
effect of MRI wave on the DSI [B(SE) = 0.012 (0.07), p = 0.85],
and (c) no significant interaction between MRI Wave and WMH
volumes [B(SE) =−2.5e-06 (8.9e-06), p = 0.78].
Cerebral venous oxygenation
Venous oxygenation is the fraction of oxygenated haemoglobin
in the venous blood. Measurements of venous oxygenation will be
used to estimate the global oxygen extraction fraction (OEF) and
global cerebral metabolic rate of oxygen consumption (CMRO2)
which are key determinants of the BOLD signal. Here, we use
T2-Relaxation-Under-Spin-Tagging (TRUST) MRI scans to non-
invasively quantify blood oxygenation in the brain, and the
theoretical frameword for this sequence has been described in
detail elsewhere (Lu and Ge, 2008; Xu et al., 2012; Jiang et al.,
2018). The pulse sequence of this scan is based on the pulsed ASL
technique. The labelling slab is placed above the imaging slice to
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FIGURE 6 | White matter hyperintensity (WMH) lesion load. (A) Data from Heart and Brain Study participant showing automatically segmented WMH at Wave MRI-1
(2012-16, blue) and Wave MRI-2 (2019-23, red), using BIANCA. Yellow arrows indicate regions with noticeable increases in WMH between the two waves.
(B) Scatter plot of BIANCA performance for 12 subjects, demonstrating that BIANCA performs similarly across the two timepoints. The Dice Similarity Index and
manually segmented WMH load (mm3) are plotted on the Y and X axes, respectively.
label venous blood. The PLD is optimised to allow sufficient blood
to be delivered to a slice placed perpendicular to the sagittal sinus.
Scans are processed using in-house MATLAB scripts, which
perform motion correction and pair-wise subtraction of the
control and label images. A region of interest is drawn around
the superior sagittal sinus, within which four voxels with the
highest blood signals (according to the difference signals) are
selected. The spatial average signal from these voxels is then fitted
to an exponential function of the effective echo time to calculate
blood R2 (transverse relaxation rate) assuming the T1 of blood as
1,624 ms. Venous oxygenation is then estimated from the blood
R2 using a calibration curve and assuming haematocrit = 0.42,
as described previously (Xu et al., 2012). OEF is expressed as a
percentage (%) of the oxygen in arterial blood extracted to serve
oxidative metabolism.
Cardiometabolic Measurements
Following a brief period of rest, participants receive
measurements of body mass index (BMI) and blood pressure.
Body Mass Index
Height (cm) and weight (kg) are measured to derive BMI as
weight/height2.
Peripheral Pressure
Peripheral blood pressure is measured using an automated
sphygmomanometer, while the participant is seated (OMRON
HEM-907; OMRON Healthcare UK Ltd., Milton Keynes). Two
measurements each of pulse rate, systolic pressure (SBP) and
diastolic pressure (DBP) are made from the right arm and
averaged. Pulse pressure is derived as SBP – DBP and mean
arterial pressure as ([SBP]+ 2[DBP])/3.
Central Blood Pressure
Pulse wave analysis (PWA) is used to estimate central blood
pressure at the level of the aorta. For this technique, a tonometer
(SphygmoCor MM3, AtCor Medical, Australia) is used to record
a peripheral pressure waveform from the right radial artery, while
the participant is seated. The peripheral pressure waveform is
used with a generalised transfer function to derive aortic SBP,
pulse pressure and other PWA parameters (Pauca et al., 2001).
Consistency of the waveform is assessed during acquisition, and
recordings are repeated if quality control criteria (i.e., operator
index ≥ 80) are not met.
Vascular Sonography
Long-term exposure to vascular risk can progressively stiffen
the aorta and other elastic arteries. The aorta branches into the
common carotid artery, which in turn bifurcates in the neck to
form the internal and external carotid arteries (which supply the
brain and rest of head, respectively). Here, ultrasound scans are
performed of the ascending aorta and left and right common
carotid arteries to qualify and quantify large artery phenotypes
such as vessel stiffness, thickness and wave transmission. Scans
are performed on a GE VIVID 7 system, in a room with
dimmed lighting. Participants are allowed 10 min of rest prior
to the scan and ECG traces are recorded concomitantly with the
ultrasound acquisitions.
Left and Right Common Carotid Arteries
Measurements are performed using an M12L linear array
transducer (centre frequency 14.0 MHz) while participants
are rested in the supine position. First, longitudinal B-mode
images of the common carotid artery are taken in the ear-
to-ear plane at a location 1–2 cm proximal to the carotid
bifurcation. Carotid wall motion is tracked for ∼20–30 heart
beats and saved as a DICOM file in order to allow offline
calculation of vessel diameter, compliance, distensibility, and β
stiffness index using specialist software (CaroLab 5.0, Zahnd
et al., 2019). Next, duplex Doppler images are taken in the
same location for a further 20–30 heartbeats, with the beam
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FIGURE 7 | Vascular duplex sonography scan of the left carotid artery showing the longitudinal image of the artery (top) and the corresponding Doppler pulse wave
velocity trace (bottom).
insonation angle maintained ≤60◦ in order to allow the
estimation of the blood velocity waveform (Figure 7), from
which the volumetric blood flow can be estimated using the
measured diameter.
Using custom-designed algorithms (Negoita et al., 2018a)
using MATLAB, R2019B, The MathWorks, MA), local carotid
artery wave speed (c) and wave intensity (WI) are then
determined in order to provide further insights into vessel
stiffness and to characterise differences in wave transmission
to-and-from the cerebral circulation. Full details of these
techniques and their clinical applicability have been published
elsewhere (Sugawara et al., 2009; Borlotti et al., 2012). In
brief, WI analysis provides a non-invasive measure of the
net energy density flux carried by forward- and backward-
travelling waves within the arterial system. During each cardiac
cycle, left ventricular contraction results in the generation of a
large forward-travelling compression wave (FCW) during early
systole which causes blood velocity and pressure to increase
in tandem. Shortly afterwards, a reflected backwards-travelling
compression wave (BCW) is commonly apparent during mid-
systole, resulting in a slowing of velocity while continuing to
increase pressure. Finally, a forward-travelling expansion wave
(FEW) generated by the onset of left ventricular relaxation is
observed at the end of systole. Here, the FCW and BCW will
be our primary WI outcomes of interest, as these have been
shown to provide information on risk of cognitive decline and
cerebrovascular vasomotor tone, respectively (Bleasdale et al.,
2003; Chiesa et al., 2019).
The non-invasive determination of the local wave speed (c)






where dlnD and dU represent simultaneous logarithmic changes
in vessel diameter and change in blood flow velocity, respectively.
The local wave speed (c) which – assuming that reflected
waves are absent during the earliest part of systole – can
be calculated from the slope of the initial linear part of a
lnDU loop.
The net WI waveform (dI) waveform can be calculated as,
dI = dD . dU
The net WI can be further separated into its forward (+) and
backward (−) travelling components using the equation:
dI± = ±
1





where +/− indicate forward and backward travelling
direction of the wave.
Ascending Aortic Artery
In addition to common carotid arteries, similar measurements
are also recorded from the ascending aorta using a 7S array
transducer (frequency 6.0 MHz), while the participant is in
the left lateral decubitus position. First, ∼20–30 heartbeats
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of continuous M-mode data are measured in the parasternal
long axis view in order to visualise changes in vessel diameter
over time, from which vessel distensibility can be calculated.
Subsequently, blood velocity is measured over a similar
timeframe in the apical five-chamber view using pulse-wave
Doppler, and custom-built MATLAB algorithms are once again
employed to trace the velocity waveform. The velocity and
diameter waveforms are then used to calculate local wave
speed and WI, as previously shown in the ascending aorta
(Negoita et al., 2018b).
Cognitive Battery
In order to evaluate longitudinal change in cognitive performance
between the two MRI waves, a subset of the same tests used at
Wave MRI-1 are administered in the same order at Wave MRI-
2. The tests have been extensively validated and shown to be
sensitive to cognitive impairment.
Montreal Cognitive Assessment
A 30-point cognitive screening test assessing visuo-
spatial abilities (4 points), short-term memory (5 points),
executive function (3 points), attention and working
memory (6 points), language and phonemic fluency (6
points), and orientation (6 points). Participants receive
an additional point if they have fewer than 12 years of
full-time education (Nasreddine et al., 2005).
Trail Making Test Versions A and B
An executive function and processing speed task where
participants connect a series of 25 circles first in ascending
numerical order (TMT-A) and then in alternating alphabetical
and numerical order (TMT-B) (Lezak et al., 2004).
The Hopkins Verbal Learning Test-Revised
A verbal learning and episodic memory task where participants
learn twelve words over three trials and recall and recognise them
immediately and after a delay of 30–45 min (Brandt, 1991).
Digit Span Test, From Wechsler’s Adult Intelligence
Scale
A working memory task where participants immediately recall
a list of numbers read to them in the forwards, backwards
and ascending order. The number of digits in each sequence
gradually increases until the participant fails or reaches a
maximum score (Wechsler et al., 2008).
Category Fluency Test, From Addenbrooke’s
Cognitive Examination Revised
A semantic memory task where participants list as many animals
as possible within 60 s (Mioshi et al., 2006).
Rey Complex Figure Test and Recognition Trial
A visuo-spatial memory, working memory, planning and
attention task, where participants copy and then recall
a complex geometric diagram immediately and after a
delay of 30–45 min (Meyers and Meyers, 1995).
Boston Naming Test
A semantic memory task, where participants name a series of 60
images of increasing difficulty (Kaplan et al., 1983).
Digit Coding Test, From the Wechsler Adult
Intelligence Scale – Fourth Edition
A working memory and executive function task where
participants have to write the appropriate novel symbol for
each number within a given time (2 min) (Wechsler et al., 2008).
Test of Premorbid Functioning
A premorbid IQ test where participants read aloud a list of
70 written words. It is marked according to pronunciation and
used to estimate intellectual functioning before disease onset
(Wechsler, 2011).
Self-Administered Clinical Questionnaire
The following self-report questionnaires which were completed
at Wave MRI-1 (and described in detail in Filippini et al. (2014))
are completed by participants in the week prior to their testing
appointment for Wave MRI-2.
Psychiatric and Psychological Questionnaires
The General Health Questionnaire-30 for detection of psychiatric
illness in community settings (Goldberg, 1988), Mood
Disorder Questionnaire for assessment of bipolar disorders
(Hirschfeld, 2002), the Centre for Epidemiological Studies
Depression (CESD) Scale for the assessment of major depressive
symptomatology (Radloff, 1977), the State and Trait Anxiety
Inventory to assess current and general anxiety (Spielberger,
1989), Penn State Worry Questionnaire (ultra-brief version) to
assess pathological worry (Berle et al., 2011), MacArthur Stress
Reactivity Questionnaire to assess reactions to stressful situations
(Taylor and Seeman, 1999), the 5-Dimensional Curiosity Scale to
gauge the desire to seek novel experiences (Kashdan et al., 2018).
Lifestyle and Life Experience Questionnaires
CHAMPS Physical Activity Questionnaire for Older Adults
to assess weekly frequency and duration of exercise (Stewart
et al., 2001), the Locus for Causality Exercise Questionnaire to
assess motivation to exercise (Miller et al., 1988), Pittsburgh
Sleep Quality Index (Buysse et al., 1989) and Jenkins
Sleep Questionnaire (Jenkins et al., 1988) to assess sleep
quality in the month prior to their visit, Life-Orientation
Revised Questionnaire to gauge optimism for future events
(Scheier et al., 1994), Life Events questionnaire to report
past stressful experiences (Brugha and Cragg, 1990), and
a Handedness questionnaire to assess preferences for right
or left-handedness (Briggs and Nebes, 1975). Participants
also provide information on the frequency of smoking
and alcohol intake.
Demographics and Medical History
Participants provide information on age, years of
education, longstanding illnesses, hospitalizations,
current or past medications, and diagnoses or self-report
of diseases.
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FIGURE 8 | Mechanistic framework for the Heart and Brain Study. The study will examine how 30-year trajectories of vascular risk throughout midlife (40–65 years)
affect cardiovascular and large artery phenotypes, cerebrovascular health, longitudinal brain atrophy and cognitive decline at older ages (>65 years). The moderating
role of genetic risk (APOE4) will also be examined.
DISCUSSION
The Heart and Brain Study will integrate trajectories of risk over
30 years, with longitudinal brain ageing and neuropsychiatric
measures, and novel cerebrovascular and cardiovascular imaging
markers. The overarching goal of this study is to identify and
understand key modifiable and genetic determinants of risk and
resilience for brain and cognitive ageing, with a primary focus
on the heart–brain axis. The following analyses were proposed
when applying for funding and will be investigated in this study
(Figure 8):
a) Disturbances in haemodynamics and biomechanical
properties of the aorta and systemic large elastic arteries
will be associated with cerebral and cognitive health.
Several studies have linked aortic stiffness with dementia
and cognitive decline (for review see Iulita et al. (2018)),
and we recently noted that faster aortic stiffening is
also related to poor brain microstructural, perfusion
and cognitive outcomes (Suri et al., 2020). Here we will
additionally examine whether this association may result
from haemodynamic changes in the carotid arteries. For
example, investigating the association between circulation
in the common carotid arteries with cerebral perfusion
from the internal carotid arteries would enable direct
inferences of how large artery circulation affects the
cerebral microvasculature.
b) Potentially modifiable vascular risk factors for dementia
will be associated cardio- and cerebrovascular outcomes
(viz. aortic and carotid phenotypes, CVR, cerebral
perfusion, WMHs, and cerebrovascular lesions) in older
age. Importantly, 30-year trajectories of vascular risk will
be assessed to determine the stage of life when their effects
on brain health may be most pronounced. The moderating
role of APOE4 in these associations will also be examined.
c) Cross-sectional MRI studies have reported associations
between CVR and cognitive impairments (for review see
Catchlove et al., 2018), and there is a well-established link
between reduced total CBF and dementia (Iadecola, 2004).
However, to date, their relationship with longitudinal brain
atrophy and cognitive decline remain poorly understood.
Here, the associations of CVR and vessel-specific CBF with
two time-point changes in vascular lesions (e.g., WMHs),
cerebral morphology (e.g., atrophy of key areas such as
the hippocampus), microstructure (e.g., changes in FA and
diffusivity) and cognitive decline (e.g., verbal memory,
executive function, spatial memory) will be examined.
The Heart and Brain Study will generate one of the most
comprehensive datasets to study the longitudinal determinants
of the heart–brain axis in ageing. The study will investigate
novel physiological mechanisms in this pathway, with a view
to describing the optimal window for managing vascular risk
in order to delay cognitive decline. We will evaluate imaging
markers for potential use in clinical trials and inform strategies to
identify at-risk individuals for targeted interventions to prevent
or delay dementia. In addition, our efforts will contribute
to the advancement and validation of MRI analysis and
harmonisation methods for longitudinal neuroimaging cohorts.
Thus, information gained from this extensively characterised
and long-running cohort will supplement ongoing larger-scale
projects such as the UK Biobank Study. Based in the Department
of Psychiatry and Wellcome Centre for Integrative Neuroimaging
at the University of Oxford, the proposed work will involve close
collaboration with neuroimaging, vascular imaging, MRI physics
and analysis, dementia research, and epidemiology experts at
University College London, Brunel University London, and the
University of Nottingham.
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